Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.

Int J Clin Pharmacol TherSep 1, 2026
Clinical ResearchOncology (Medical)

Li-Wen Zhang, An Huang, Hong-Fang Ma et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the efficacy and safety of bisphosphonates in reducing skeletal-related events in 14,934 patients with bone metastases from breast cancer. Clodronate was found to be the most effective in reducing pathological fractures, with a significant difference compared to pamidronate (OR = -1.41) and zoledronate (OR = -1.44).

Key findings

  • Clodronate was most effective in reducing pathological fractures compared to other bisphosphonates.
  • Significant differences in fracture reduction were noted between clodronate and pamidronate, and clodronate and zoledronate.
  • Zoledronate was more effective than clodronate and pamidronate for hypercalcemia reduction, though not statistically significant.
  • Ibandronate had fewer adverse reactions than clodronate and zoledronate, with a significant difference from zoledronate.

Why it matters

Understanding the comparative efficacy and safety of bisphosphonates can guide clinicians in selecting appropriate treatments for patients with bone metastases from breast cancer, potentially improving patient outcomes.

Source

PubMed · PMID 42290268

Published in Int J Clin Pharmacol Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.